BioSpace News Archive

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Thermo Scientific NanoDrop Eight UV-Vis Microvolume Spectrophotometer, a robust, easy-to-use spectrophotometer that replaces the NanoDrop 8000.

Endeavor BioMedicines, a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, announced that the company has dosed its first patient in a Phase 2 trial of taladegib (ENV-101) to treat idiopathic pulmonary fibrosis (IPF).

KSQ Therapeutics today announced that Qasim Rizvi, Chief Executive Officer of KSQ, will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 4:40 PM (ET).

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq’s minimum bid price requirement.

EXUMA Biotech, Corp. today announced that Chairman and Chief Executive Officer, Gregory Frost , Ph.D., will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29th, 2021, from 2:40-3:10 p.m. ET.

Inspira Technologies OXY B.H.N. Ltd announced that the the ART’s device “brain” is to acquire an algorithm enhanced digital platform, for which the Company has contracted GlobalLogic, a Hitachi Group Company, a world leader in digital product engineering.

Leap Therapeutics, Inc. today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85 per share and of pre-funded warrants to purchase shares of its common stock

Legend Biotech Corporation will host its first Research & Development Day on Monday, October 18, commencing at 10:00 a.m. (Eastern Time), at Andaz 5th Avenue in New York.

CinFina Pharma, LLC. announced that it has signed an agreement with Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to acquire exclusive global rights to GDF-15 and PYY analogs and GLP-1/GDF-15 and GLP/PYY dual agonists.

Amgen released the 8th edition of the Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feature considers how advancements in biosimilars can support the long-term success and sustainability of the U.S. healthcare system.